Abstract:

Renal impairment (RI) is a major comorbidity in patients with multiple myeloma (MM). Here we present the pooled safety and efficacy analysis of three clinical trials (MM-002, MM-003, and MM-010) of pomalidomide + low-dose dexamethasone (POM + LoDEX) in patients with moderate RI (creatinine clearance [CrCl] ≥ 30 to <60 mL/min) and without RI (≥ 60 mL/min). Trial protocols were approved by the institutional review board of each site involved. Patients with RI were older than patients without RI, although other baseline characteristics were similar. The dosing and safety profile of POM + LoDEX was similar across RI subgroups. Median overall response rate, progression-free survival, time to progression, and duration of response were not significantly different between RI subgroups. However, patients with vs. without RI had significantly shorter median overall survival (10.5 vs. 14.0 months, respectively; p =.004). This analysis demonstrates that POM + LoDEX is a safe and effective treatment for patients with moderate RI. The trials were registered at ClinicalTrials.gov as NCT00833833 (MM-002), NCT01311687 (MM-003), and NCT01712789 (MM-010) and at EudraCT as 2010-019820-30 (MM-003) and 2012-001888-78 (MM-010). © 2016 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

Notes:

Cited By :1Export Date: 18 February 2017References: Korbet, S.M., Schwartz, M.M., Multiple myeloma (2006) J Am Soc Nephrol, 17, pp. 2533-2545;Kastritis, E., Anagnostopoulos, A., Roussou, M., Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents (2007) Haematologica, 92, pp. 546-549; Dimopoulos, M.A., Delimpasi, S., Katodritou, E., Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents (2014) Ann Oncol, 25, pp. 195-200; Kyle, R.A., Gertz, M.A., Witzig, T.E., Review of 1027 patients with newly diagnosed multiple myeloma (2003) Mayo Clin Proc, 78, pp. 21-33; Dimopoulos, M.A., Terpos, E., Chanan-Khan, A., Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group (2010) J Clin Oncol, 28, pp. 4976-4984; Chanan-Khan, A.A., San Miguel, J.F., Jagannath, S., Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment (2012) Clin Cancer Res, 18, pp. 2145-2163; Goldschmidt, H., Lannert, H., Bommer, J., Multiple myeloma and renal failure (2000) Nephrol Dial Transplant, 15, pp. 301-304; Knudsen, L.M., Hjorth, M., Hippe, E., Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group (2000) Eur J Haematol, 65, pp. 175-181; Dimopoulos, M.A., Rossou, M., Gkotzmanidou, M., The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma (2013) Leukemia, 27, pp. 423-429; Uttervall, K., Duru, A.D., Lund, J., The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment (2014) PLoS One, 9, p. e101819; Attal, M., Harousseau, J.L., Leyvraz, S., Maintenance therapy with thalidomide improves survival in patients with multiple myeloma (2006) Blood, 108, pp. 3289-3294; Kumar, S.K., Rajkumar, S.V., Dispenzieri, A., Improved survival in multiple myeloma and the impact of novel therapies (2008) Blood, 111, pp. 2516-2520; Gonsalves, W.I., Leung, N., Rajkumar, S.V., Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma (2015) Blood Cancer J, 5, p. e296; Quach, H., Ritchie, D., Stewart, A.K., Mechanism of action of immunomodulatory drugs (IMiDs) in multiple myeloma (2010) Leukemia, 24, pp. 22-32; Dimopoulos, M.A., Palumbo, A., Corradini, P., The STRATUS (MM-010) trial: a single-arm, phase 3B study evaluating safety and efficacy of pomalidomide + low-dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma (2015) Haematologica, 100, p. 273; Richardson, P.G., Siegel, D.S., Vij, R., Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study (2014) Blood, 123, pp. 1826-1832; San Miguel, J., Weisel, K., Moreau, P., Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial (2013) Lancet Oncol, 14, pp. 1055-1066; (2015) Pomalyst (pomalidomide) [package insert], , Summit, NJ: Celgene Corporation; (2015) Imnovid (pomalidomide) [summary of product characteristics], , Uxbridge, UK: Celgene Europe; Botev, R., Mallie, J.P., Wetzels, J.F., The clinician and estimation of glomerular filtration rate by creatinine-based formulas: current limitations and quo vadis (2011) Clin J Am Soc Nephrol, 6, pp. 937-950; K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification (2002) Am J Kidney Dis, 39, pp. S1-S266; Chen, N., Lau, H., Kong, L., Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis (2007) J Clin Pharmacol, 47, pp. 1466-1475; Dimopoulos, M.A., Christoulas, D., Roussou, M., Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment (2010) Eur J Haematol, 85, pp. 1-5; Hoffmann, M., Kasserra, C., Reyes, J., Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration (2013) Cancer Chemother Pharmacol, 71, pp. 489-501; Cockcroft, D.W., Gault, M.H., Prediction of creatinine clearance from serum creatinine (1976) Nephron, 16, pp. 31-41; Weisel, K.C., Dimopoulos, M.A., Moreau, P., Analysis of MM-003 patients with moderate renal impairment using pomalidomide + low-dose dexamethasone (POM + LoDEX) vs. high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM) (2013) Haematologica, 98, p. 244; Leleu, X., Attal, M., Arnulf, B., Pomalidomide plus low dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02 (2013) Blood, 121, pp. 1968-1975; Richardson, P.G., Siegel, D., Baz, R., Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib (2013) Blood, 121, pp. 1961-1967; Weisel, K., Dimopoulos, M., Moreau, P., Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): MM-003 analysis of patients (pts) with moderate renal impairment (RI) (2013) J Clin Oncol, p. 8527; Siegel, D.S., Richardson, P.G., Baz, R., Pomalidomide (POM) with low-dose dexamethasone (LoDEX) in patients with relapsed and refractory multiple myeloma (RRMM): impact of renal function on patient outcomes (2012) Blood, 120, p. 4072; Dimopoulos, M.A., Leleu, X., Palumbo, A., Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma (2014) Leukemia, 28, pp. 1573-1585; Matous, J., Siegel, D., Lonial, S., MM-008: a phase 1 trial evaluating pharmacokinetics and tolerability of pomalidomide + low-dose dexamethasone in patients with relapsed or refractory and refractory multiple myeloma and renal impairment (2014) Blood, 124, p. 4730; Sonneveld, P., Heyne, N., Kueenburg, E., MM-013: an ongoing phase 2 trial of pomalidomide and low-dose dexamethasone (POM + LoDEX) in relapsed/refractory multiple myeloma (RRMM) with moderate or severe renal impairment (RI), including patients (pts) undergoing hemodialysis (2014) J Clin Oncol, 32, p. TPS8626

Website